-
Veteran Banker Joins Avextra’s Supervisory Board
Bensheim, Germany, April 3, 2025 – Dr. Stefan Jentzsch, Partner at the global investment firm Perella Weinberg Partners has been appointed to Avextra’s Supervisory Board, bringing decades of experience in corporate finance, M&A, and investment banking to the company…
-
Avextra Showcases Study Findings on World Sleep Day 2025
Bensheim, 14. März 2025 – Im Rahmen des Weltschlaftags hat Avextra Ergebnisse der IMPACT-Studie auf den Deutschen Schmerz- und Palliativtagen vorgestellt, die von der Deutschen Gesellschaft für Schmerzmedizin e.V. (DGS) veranstaltet werden…
-
Avextra Unveils Promising Study Results at Major Pain Congress
Bensheim – 13. März 2025 – Bei den Deutschen Schmerz- und Palliativtagen stellt die DGS heute Ergebnisse der retrospektiven Registerstudie OCEAN-R vor, die von dem deutschen Biotech-Unternehmen Avextra unterstützt wurde…
-
Avextra expanding its product portfolio of cannabis-based medicines
Bensheim, Germany, 6 March 2025 — Avextra is broadening its product portfolio with a 25/25 cannabis extract and is presenting initial study results during the German Pain and Palliative Care Days…
-
Avextra Portugal Unveils Advanced Breeding Program to Develop Proprietary THC and CBD Cultivars, Establishing a Key IP Pillar
Lisbon, Portugal, November 20, 2024 — Avextra Portugal is excited to announce that its innovative in-house breeding program is now operational…
-
Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial
Bensheim, Germany, Oct. 08, 2024 — Avextra AG…
-
German start-up Avextra wants to develop “cannabis blockbusters”.
The Leading German Business Publication Handelsblatt did a profile on the German cannabis biotech company Avextra providing insights into botanical drug development Made in Germany.
-
Avextra AG and SynQube GmbH announce a Strategic Partnership in Drug Development
Avextra and SynQube jointly announce their strategic partnership. Both partners are combining their extensive expertise in the field of cannabinoid therapy to improve patient care and fulfill the requirements for reimbursement.
-
Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors
BENSHEIM, Germany, Feb. 07, 2024 (GLOBE NEWSWIRE) — Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is proud to announce the closing of its most recent capital raise with support from existing investors, strategic partners and new institutional investors. The funding will…
-
German Pain Association (DGS) and pharmaceutical company Avextra join forces to launch their new study OCEAN
Bensheim, Germany, January 23, 2024 – Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is proud to announce a joint study with the German Pain Association (DGS) focused on chemotherapy-induced neuropathic pain (CINP).
